PF-07104091 (PF07104091) is a novel and orally bioavailable inhibitor of cyclin-dependent kinase 2 (CDK2) with potential anticancer activity. PF-07104091 has 100-fold selectivity against CDK1, 200 to 400-fold selectivity against CDK4 and CDK6, 170-fold selectivity against CDK9, and greater than 500-fold selectivity against GSK3B. In a tumor growth inhibition study in an ovarian cancer model, single-agent PF-07104091 demonstrated a dose-dependent tumor growth reduction with 86 percent maximal effect and demonstrated single-agent efficacy across multiple ovarian models. PF-07104091 also re-established cell-cycle control in cancer types where CDK4/6 inhibitors lack efficacy. PF-07104091 is currently being tested in phase I/IIa dose escalation trial with the first patient dosed in October 2020. PF-07104091 may be used for the treatment of cyclinE-amplified cancers. CDK2, a member of a large family of cyclin dependent kinases, requires binding to a regulatory cyclin subunit, such as A or E.

纯度：≥98%

CAS：2460249-19-6